Jerome Deval
Overview
Explore the profile of Jerome Deval including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
1569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vendeville S, Amblard F, Bassit L, Beigelman L, Blatt L, Chen X, et al.
J Med Chem
. 2024 Nov;
67(23):21126-21142.
PMID: 39575679
Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce...
2.
Vandyck K, McGowan D, Luong X, Stevens S, Jekle A, Gupta K, et al.
J Med Chem
. 2024 Sep;
67(17):14840-14851.
PMID: 39221768
Agonists of thyroid hormone receptor β (THR-β) decreased LDL cholesterol (LDL-C) and triglyceride (TG) levels in human clinical trials for patients with dyslipidemia. The authors present the highly potent and...
3.
Bonneux B, Shareef A, Tcherniuk S, Anson B, De Bruyn S, Verheyen N, et al.
Antiviral Res
. 2024 May;
227:105907.
PMID: 38772503
Respiratory syncytial virus (RSV) can cause pulmonary complications in infants, elderly and immunocompromised patients. While two vaccines and two prophylactic monoclonal antibodies are now available, treatment options are still needed....
4.
Jekle A, Thatikonda S, Jaisinghani R, Ren S, Kinkade A, Stevens S, et al.
Int J Mol Sci
. 2023 Nov;
24(22).
PMID: 38003463
Stimulator of interferon genes (STING) agonists have shown potent anti-tumor efficacy in various mouse tumor models and have the potential to overcome resistance to immune checkpoint inhibitors (ICI) by linking...
5.
Vanrusselt H, Kum D, Taverniti V, Liu C, Sanchez A, Corthout N, et al.
J Virol
. 2023 Sep;
97(10):e0072223.
PMID: 37754761
Chronic hepatitis B is the most important cause of liver cancer worldwide and affects more than 290 million people. Current treatments are mostly suppressive and rarely lead to a cure....
6.
Kum D, Vanrusselt H, Sanchez A, Taverniti V, Verrier E, Baumert T, et al.
Hepatology
. 2023 Apr;
78(4):1252-1265.
PMID: 37102495
Background And Aims: Effective therapies leading to a functional cure for chronic hepatitis B are still lacking. Class A capsid assembly modulators (CAM-As) are an attractive modality to address this...
7.
Jochmans D, Liu C, Donckers K, Stoycheva A, Boland S, Stevens S, et al.
mBio
. 2023 Jan;
14(1):e0281522.
PMID: 36625640
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select...
8.
Spengler J, Welch S, Deval J, Gentry B, Brancale A, Carter K, et al.
Antiviral Res
. 2023 Jan;
211:105521.
PMID: 36596323
The 35th International Conference on Antiviral Research (ICAR), sponsored by the International Society for Antiviral Research (ISAR), was held in Seattle, Washington, USA, on March 21-25, 2022 and concurrently through...
9.
Brancale A, Carter K, Delang L, Deval J, Durantel D, Gentry B, et al.
Antivir Chem Chemother
. 2022 Oct;
30:20402066221130853.
PMID: 36305015
As a result of the multiple gathering and travels restrictions during the SARS-CoV-2 pandemic, the annual meeting of the International Society for Antiviral Research (ISAR), the International Conference on Antiviral...
10.
Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex
Deval J, Gurard-Levin Z
Molecules
. 2022 May;
27(9).
PMID: 35566268
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic. While the development of vaccines and the emergence of antiviral therapeutics is promising, alternative strategies to...